LA JOLLA, Calif., November 12, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer. Dual and synergistic signaling of IL-15 and IL-21 robustly augments NK and CD8 T cell responses.